Director · Spyre Therapeutics, Inc. · Spyre Therapeutics, Inc. — Stock Option (Right to Buy)
Side
A
Value
—
Shares
8,026
Price
—
Executed
May 27, 2026
Disclosed
May 29, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
May 27 executedMay 29, 2026 disclosed
SYRE · daily
Yahoo Finance chart API
◉This trade, on the day it was made▼Disclosure●Material company filing◯Other disclosed buy◯Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Grant or award — administrative, little informational value
Relative size+1 / 25
No reported dollar value · new position
Filing timing0 / 15
Disclosed 2 business days after execution (deadline: 2)
Historical behavior+8 / 15
First recorded trade by this actor in this security
Frequency & clustering0 / 15
No clustered activity in the dataset
Market events0 / 10
No material company filing within 60 days after the trade
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
Spyre Therapeutics, Inc. — Stock Option (Right to Buy)
Ticker
SYRE
Shares
8,026
Price per share
$0
Execution date (reported)
May 27, 2026
Owned after transaction
8,026 shares
Days from execution to publication
2
What this establishes
Milligan Sandra filed this Form 4 reporting a grant or award of SYRE on May 27, 2026. It became public on May 29, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
Director
Milligan Sandracik:0001859810
Issuer
Spyre Therapeutics, Inc.cik:0001636282
Revision history · 0
No field has changed since this record was first ingested.
